Abbott is aiming to capture share from Boston Scientific in the market for devices that seal the heart’s left atrial ...
The next-generation minimally invasive device is designed to reduce the risk of stroke in patients with non-valvular atrial ...
Although transesophageal echocardiography (TEE) is recommended when performing percutaneous left atrial appendage (LAA) occlusion, there may be a way to complete the procedure without the assistance ...
A left atrial appendage (LAA) closure device provides long-term thromboembolic protection that is equivalent to direct oral anticoagulants after ablation for atrial fibrillation (AF), along with a ...
Chicago, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The global left atrial appendage closure devices market was valued at US$ 1.98 billion in 2024 and is expected to reach US$ 9.40 billion by 2033, growing at ...
The left atrial appendage (LAA), a site of predilection for thrombus formation, is the primary source of thromboemboli in patients with nonvalvular atrial fibrillation (NVAF) who have a stroke ...
ORLANDO, FL—Left atrial appendage (LAA) closure remained noninferior to direct oral anticoagulants (DOACs) in terms of preventing major cardiovascular and neurological events, as well as clinically ...
NEW ORLEANS -- It may be reasonable for people with atrial fibrillation (Afib) to undergo percutaneous left atrial appendage (LAA) closure even if long-term anticoagulation is an alternative, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results